$616 Million is the total value of GREAT POINT PARTNERS LLC's 33 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 85.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GWPH | Sell | GW PHARMACEUTICALS PLCads | $45,010,000 | -11.1% | 390,000 | -25.0% | 7.31% | +60.5% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $42,569,000 | -66.6% | 917,427 | -76.3% | 6.91% | -39.8% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $39,312,000 | -67.3% | 454,417 | -76.9% | 6.38% | -41.0% |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $38,518,000 | -51.4% | 720,502 | -62.5% | 6.26% | -12.3% |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $38,388,000 | – | 700,000 | +100.0% | 6.24% | – |
| ZYME | Sell | ZYMEWORKS INC | $37,795,000 | -48.2% | 799,722 | -49.0% | 6.14% | -6.6% |
| XENT | Buy | INTERSECT ENT INC | $29,836,000 | +144.6% | 1,302,871 | +74.2% | 4.85% | +341.8% |
| CNST | Sell | CONSTELLATION PHARMCETICLS I | $29,514,000 | -49.1% | 1,024,800 | -64.2% | 4.79% | -8.1% |
| MGNX | Sell | MACROGENICS INC | $28,330,000 | -25.5% | 1,239,287 | -17.9% | 4.60% | +34.5% |
| VCEL | Sell | VERICEL CORP | $27,792,000 | +1.3% | 900,000 | -39.2% | 4.51% | +82.9% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $26,516,000 | -64.4% | 345,120 | -65.4% | 4.31% | -35.8% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $25,790,000 | -28.7% | 595,473 | -9.2% | 4.19% | +28.8% |
| UTHR | Sell | UNITED THERAPEUTICS CORP DEL | $22,769,000 | -64.8% | 150,000 | -76.6% | 3.70% | -36.5% |
| OCUL | New | OCULAR THERAPEUTIX INC | $17,723,000 | – | 856,162 | +100.0% | 2.88% | – |
| KDMN | Buy | KADMON HLDGS INC | $16,948,000 | +72.9% | 4,083,909 | +63.4% | 2.75% | +212.1% |
| PODD | New | INSULET CORP | $15,338,000 | – | 60,000 | +100.0% | 2.49% | – |
| TBPH | New | THERAVANCE BIOPHARMA INC | $14,653,000 | – | 824,580 | +100.0% | 2.38% | – |
| ARVN | New | ARVINAS INC | $13,941,000 | – | 164,150 | +100.0% | 2.26% | – |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $13,338,000 | +19.9% | 1,300,000 | +18.0% | 2.17% | +116.6% |
| MRSN | New | MERSANA THERAPEUTICS INC | $12,971,000 | – | 487,452 | +100.0% | 2.11% | – |
| PRTA | Sell | PROTHENA CORP PLC | $11,742,000 | -24.1% | 977,647 | -36.9% | 1.91% | +37.0% |
| EXEL | New | EXELIXIS INC | $9,533,000 | – | 475,000 | +100.0% | 1.55% | – |
| CALA | Sell | CALITHERA BIOSCIENCES INC | $9,059,000 | -10.0% | 1,845,000 | -36.8% | 1.47% | +62.4% |
| COLL | New | COLLEGIUM PHARMACEUTICAL INC | $8,440,000 | – | 421,383 | +100.0% | 1.37% | – |
| FMTX | New | FORMA THERAPEUTICS HLDGS INC | $8,250,000 | – | 236,400 | +100.0% | 1.34% | – |
| GERN | Sell | GERON CORP | $8,038,000 | -52.3% | 5,055,189 | -47.8% | 1.31% | -13.9% |
| FGEN | New | FIBROGEN INCcall | $6,176,000 | – | 166,500 | +100.0% | 1.00% | – |
| LUNG | New | PULMONX CORP | $4,441,000 | – | 64,345 | +100.0% | 0.72% | – |
| IONS | New | IONIS PHARMACEUTICALS INC | $4,241,000 | – | 75,000 | +100.0% | 0.69% | – |
| SBTX | New | SILVERBACK THERAPEUTICS INC | $3,244,000 | – | 70,000 | +100.0% | 0.53% | – |
| CALA | New | CALITHERA BIOSCIENCES INCcall | $2,455,000 | – | 500,000 | +100.0% | 0.40% | – |
| AUPH | Sell | AURINIA PHARMACEUTICALS INC | $2,420,000 | -93.4% | 175,000 | -93.0% | 0.39% | -88.1% |
| MLND | Sell | MILLENDO THERAPEUTICS INC | $578,000 | -69.9% | 270,000 | -77.1% | 0.09% | -45.7% |
| OYST | Exit | OYSTER PT PHARMA INC | $0 | – | -70,121 | -100.0% | -0.13% | – |
| ABEO | Exit | ABEONA THERAPEUTICS INC | $0 | – | -3,892,921 | -100.0% | -0.36% | – |
| CYTK | Exit | CYTOKINETICS INCput | $0 | – | -253,000 | -100.0% | -0.49% | – |
| LQDA | Exit | LIQUIDIA TECHNOLOGIES INC | $0 | – | -1,189,607 | -100.0% | -0.53% | – |
| LNTH | Exit | LANTHEUS HLDGS INC | $0 | – | -594,750 | -100.0% | -0.68% | – |
| VRAY | Exit | VIEWRAY INC | $0 | – | -2,655,763 | -100.0% | -0.84% | – |
| IVA | Exit | INVENTIVA SAads | $0 | – | -999,422 | -100.0% | -1.06% | – |
| ALLO | Exit | ALLOGENE THERAPEUTICS INC | $0 | – | -328,817 | -100.0% | -1.12% | – |
| TBIO | Exit | TRANSLATE BIO INC | $0 | – | -943,339 | -100.0% | -1.16% | – |
| CCXI | Exit | CHEMOCENTRYX INC | $0 | – | -253,230 | -100.0% | -1.25% | – |
| SGMO | Exit | SANGAMO THERAPEUTICS INC | $0 | – | -1,589,724 | -100.0% | -1.35% | – |
| GKOS | Exit | GLAUKOS CORP | $0 | – | -446,097 | -100.0% | -1.99% | – |
| BHVN | Exit | BIOHAVEN PHARMACTL HLDG CO L | $0 | – | -435,000 | -100.0% | -2.54% | – |
| TGTX | Exit | TG THERAPEUTICS INC | $0 | – | -1,600,000 | -100.0% | -3.85% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -2,549,525 | -100.0% | -4.96% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.